Search

Merck announced positive top-line results from its pivotal Phase 3 trial evaluating the company's 9-valent Human Papillomavirus vaccine, GARDASIL 9 in Japanese males ages 16 to 26 years. The trial [...]

Merck, known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine [...]

Merck, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, [...]

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that China National Medical Products Administration (NMPA) has accepted its investigational new [...]

YS Biopharma announced that its PIKA Rabies Vaccine was granted Phase 3 clinical trial approval from the FDA of the Philippines. The Phase 3 clinical trial, which is planned to [...]

YS Biopharma announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan. The Phase 3 clinical trial will evaluate the safety [...]

Ault Alliance (AULT) announced that Alzamend Neuro (ALZN) has initiated its Phase I/IIA clinical trial for its immunotherapeutic vaccine to treat mild to moderate dementia of the Alzheimer's type. The [...]

Dyadic International announced that it has received regulatory approval of a Clinical Trial Application, CTA, from the South African Health Products Regulatory Authority, SAHPRA, to initiate a Phase 1 clinical [...]

Icosavax announced positive topline interim results from its Phase 1/1b clinical trial of IVX-121, a VLP displaying a prefusion stabilized Respiratory Syncytial Virus RSV F antigen, in young and older [...]

Agenus shared that partner GSK announced headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial evaluating their investigational RSV vaccine in adults aged 60 [...]

HilleVax reported dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company's virus-like particle based vaccine candidate, for the prevention of moderate-to-severe acute [...]

Valneva SE, a specialty vaccine company, and Pfizer Inc. reported positive phase 2 paediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer [...]

Valneva (VALN) and Pfizer (PFE) reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with [...]

Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain, RBD. Adam Simpson, Chief Executive Officer of [...]

Valneva SE, a specialty vaccine company, and Pfizer Inc. reported further positive phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer [...]

Icosavax announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus stabilized pre-fusion F antigen, in healthy adults and older adults. Assuming [...]

Novavax announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19. The additional arm of the [...]

Dynavax announced that Valneva SE reported initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018 adjuvant in [...]

CureVac N.V. announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being evaluated in [...]

Byline: The Indian Practitioner Serum Institute of India is now preparing for the phase 3 clinical trials of the COVID-19 vaccine candidate developed by the University of Oxford, after interim [...]

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: 'We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell [...]

Inovio, a biotechnology company, announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two phase 1 clinical trial cohorts. In addition, INO-4800 [...]

INOVIO announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus, or SARS-CoV-2, from the first two Phase 1 clinical trial cohorts. In addition, INO-4800 has been [...]

The U.S. government plans to fund the Phase 3 studies of three experimental coronavirus vaccines starting this summer, Peter Loftus of Wall Street Journal reports, citing an interview with John [...]

Pfizer (PFE) and BioNTech (BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. [...]

Byline: Mainz BioNTech and Pfizer have announced that the first cohort of BioNTechÇÖs phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in [...]

Inovio announced that its phase 1 US clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses [...]

BioNTech SE (BNTX) and Pfizer (PFE) have announced that the first cohort of BioNTech's Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 [...]

INOVIO announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses [...]

BioNTech SE (BNTX) and Pfizer (PFE) disclosed additional details of their collaboration to advance candidates from BioNTech's mRNA vaccine program, previously announced on March 17, 2020. The collaboration aims to [...]

Arcturus Therapeutics announced plans to initiate a human clinical trial this Summer for its COVID-19 vaccine, also known as LUNAR-COV19. Under the guidance of the Singapore Health Sciences Authority, the [...]